Is First Wave Biopharma, Inc. overvalued or undervalued?

Jun 25 2025 09:08 AM IST
share
Share Via
As of October 5, 2023, First Wave Biopharma, Inc. is considered attractive and undervalued, with a price-to-earnings ratio of 12.5, a price-to-book ratio of 1.8, and a return on equity of 15%, outperforming peers like Amgen and Gilead Sciences.
As of 5 October 2023, First Wave Biopharma, Inc. moved from fair to attractive. The company is currently undervalued based on its financial metrics. Key ratios include a price-to-earnings ratio of 12.5, a price-to-book ratio of 1.8, and a return on equity of 15%.

In comparison to its peers, such as Amgen with a price-to-earnings ratio of 15.2 and Gilead Sciences at 11.0, First Wave Biopharma presents a more favorable valuation. This suggests that the market may not fully recognize the company's growth potential. Recent stock performance has also shown resilience against the Sensex, reinforcing the notion that the stock is undervalued relative to its fundamentals.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
First Wave Biopharma Hits New 52-Week High at $5.20
Sep 18 2025 01:22 PM IST
share
Share Via
First Wave Biopharma Hits New 52-Week High of $4.61
Sep 17 2025 03:20 PM IST
share
Share Via
First Wave Biopharma Hits New 52-Week High of $3.67
Sep 16 2025 11:30 AM IST
share
Share Via
What does First Wave Biopharma, Inc. do?
Jun 22 2025 06:51 PM IST
share
Share Via
Most Read
Why is Bluestone Jewel falling/rising?
1 hour ago
share
Share Via
Why is Borana Weaves falling/rising?
1 hour ago
share
Share Via
Why is Malpani Pipes falling/rising?
1 hour ago
share
Share Via
Why is Sat Kartar falling/rising?
1 hour ago
share
Share Via
Why is Baazar Style falling/rising?
1 hour ago
share
Share Via
Why is Blackbuck falling/rising?
1 hour ago
share
Share Via